All In Biotech

Drug Trial Radar · NCT00163137

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Aug 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

540

Actual

Start

May 2003

Primary completion

Oct 2005

Study completion Oct 2005

Sponsor

Lead sponsor
Ligand PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 48 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.

Conditions

  • Osteoporosis

Interventions

  • lasofoxifeneDrug

    lasofoxifene 0.25mg

  • raloxifeneDrug

    raloxifene 60 mg/day

  • PlaceboDrug

    0 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Spine BMD after 2 yearsTime frame: 2 years

Locations

72 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Albany, California

  • Pfizer Investigational Site

    Berkeley, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    Oakland, California

  • Pfizer Investigational Site

    Oakland, California

  • Pfizer Investigational Site

    Palo Alto, California

  • Pfizer Investigational Site

    Poway, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Brandon, Florida

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Key Largo, Florida

  • Pfizer Investigational Site

    Lake Worth, Florida

  • Pfizer Investigational Site

    Leesburg, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Des Moines, Iowa

  • Pfizer Investigational Site

    Wichita, Kansas

  • Pfizer Investigational Site

    Portland, Maine

  • Pfizer Investigational Site

    Bethesda, Maryland

  • Pfizer Investigational Site

    Gaithersberg, Maryland

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Southfield, Michigan

  • Pfizer Investigational Site

    Arden Hills, Minnesota

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Akron, Ohio

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.